Out-of-pocket spending on insulin among people with private insurance March 24, 2022 Issue Brief This analysis of insurance claims data finds that Congressional proposals to set a $35 per month cap on what people pay out of pocket for insulin would provide financial relief to at least 1 out of 5 insulin users with different types of private health insurance.
About 1 in 20 People with Private Insurance Received Services that Could be Affected by a District Court Ruling Limiting the ACA’s Preventive Services Mandate May 25, 2023 News Release A new KFF analysis finds about 1 in 20 privately insured people (5.7%) received at least one ACA preventive service or drug that could be affected by a now-stayed U.S. District Court ruling in Braidwood Management v. Becerra, which found the Affordable Care Act’s (ACA) preventive services mandate partially unconstitutional.…
What to Know About the FDA’s Recent Decision to Allow Florida to Import Prescription Drugs from Canada January 12, 2024 Blog Florida’s plan to import certain prescription drugs from Canada represents the first time the Food and Drug Administration (FDA) has granted authority for a state to safely import prescription drugs from another country. This policy watch analysis unpacks some frequently asked questions related to state of Florida’s importation plan, including potential obstacles to implementation, who will benefit from any savings, and what types of drugs will (and will not) qualify for importation.
Florida’s Plan to Import Prescription Drugs from Canada, the First of its Kind, May Face Obstacles that Could Delay Implementation and Savings January 12, 2024 News Release A new KFF policy watch explains some of the hurdles the state of Florida still must clear before it can implement its novel plan to make some prescription drugs more affordable by importing them from Canada. Florida’s plan represents the first time the Food and Drug Administration (FDA) has granted…
The 4 Arguments You Will Hear Against Drug Price Negotiation September 6, 2023 Perspective As the Biden administration begins the process of negotiation drug prices for Medicare as authorized in the Inflation Reduction Act, KFF’s Larry Levitt probes some of the arguments against it and the policy and political implications of the debate in this New York Times op-ed column.
Health Care Costs Top the Public’s List of Financial Worries, and Those Who Are Struggling the Most Want to Hear Presidential Candidates Discuss Economic and Health Care Issues February 21, 2024 News Release At a time when kitchen table economic problems are on voters’ minds, unexpected medical bills and health care costs top the public’s list of financial concerns, and voters who are struggling to pay their monthly bills are the most eager to hear the presidential candidates talk about economic and health…
KFF Health Tracking Poll: Economic Views and Experiences of Adults Who Struggle Financially February 21, 2024 Poll Finding Half of adults say they have difficulty affording monthly bills or are just able to afford household expenses without having money left over. These groups overwhelmingly rate the economy negatively and are more likely to want 2024 presidential candidates to discuss economic issues.
Explaining the Prescription Drug Provisions in the Inflation Reduction Act January 24, 2023 Issue Brief The Inflation Reduction Act includes several provisions that will lower prescription drug costs for people with Medicare and reduce drug spending by the federal government. This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation.
FAQs about the Inflation Reduction Act’s Medicare Drug Price Negotiation Program January 31, 2024 Issue Brief The Centers for Medicare & Medicaid Services (CMS) recently issued initial guidance describing CMS’s plans for implementation of the new Medicare Drug Price Negotiation Program, which was established by the Inflation Reduction Act. These FAQs address several questions related to Medicare’s drug price negotiation program and how CMS intends to implement the new program, with a focus on the details that apply for 2026, the first year that negotiated prices will be available under this new program.
3 Charts: Medicare Drug Price Negotiations January 31, 2024 News Release Under the Inflation Reduction Act, the federal government for the first time will negotiate directly with drug companies to determine the prices that Medicare will pay for certain high expenditure drugs covered under Medicare Part D (starting in 2026) and Part B (starting in 2028). Part D covers retail prescription…